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Entamoeba histolytica is an invasive intestinal pathogenic parasitic protozoan that causes amebiasis. It must be distinguished from
Entamoeba dispar and E. moshkovskii, nonpathogenic commensal parasites of the human gut lumen that are morphologically
identicaltoE.histolytica.DetectionofspeciﬁcE.histolyticaantigensinstoolsisafast,sensitivetechniquethatshouldbeconsidered
as the method of choice. Stool real-time PCR is a highly sensitive and speciﬁc technique but its high cost make it unsuitable for
use in endemic areas where there are economic constraints. Serology is an important component of the diagnosis of intestinal and
especially extraintestinal amebiasis as it is a sensitive test that complements the detection of the parasite antigens or DNA. Circu-
lating Gal/GalNac lectin antigens can be detected in the serum of patients with untreated amoebic liver abscess. On the horizon are
multiplex real-time PCR assays which permit the identiﬁcation of multiple enteropathogens with high sensitivity and speciﬁcity.
Copyright © 2009 Anjana Singh et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The World Health Organization (WHO) ranks diarrheal
disease as the second highest cause of morbidity and
mortality in children in the developing world [1–3]. Enteric
protozoa are one case of diarrheal disease in children.
Intestinal protozoa are transmitted by the fecal-oral route
and exhibit life cycles consisting of a cyst stage and a
trophozoite stage. The cysts consist of a resistant wall and
are excreted in the feces. The cyst wall functions to protect
the organism from desiccation in the external environment.
Unhygienic conditions promote transmission of most pro-
tozoa. Traditionally parasites have been identiﬁed by simple
microscopy and serologic methods. New approaches include
antigen detection and PCR [4–7].
2.IntestinalParasites:
Cryptosporidium, Cyclospora,
Entamoeba spp., Giardia, Isospora
2.1. Cryptosporidium. The genus Cryptosporidium was iden-
tiﬁed in mice by Edward Tyzzer in 1907 [3]. It was found
as human pathogen in 1976. Many species infect humans
and a wide range of animals. Cryptosporidium parvum and
Cryptosporidium hominis are the most prevalent species
causing disease in humans [8]. Human cryptosporidiosis
is also seen with C. felis, C. meleagridis, C. canis, C. suis,
and C. muris [9–11]. In developing countries Cryptosporium
spp. infections occur mostly in children younger than ﬁve
years, with most under two years of age [12, 13]. C. hominis
is the genus which infects only humans while C. parvum
infects humans and cattle [11]. Recent literature shows that
C. hominis is the commonest strain found in human stools
[9, 14]. Each oocyst measures about 5.2 × 4.6m i c r o m e t e r s
and contains four infective sporozoites. Recently C. hominis
subgenotyping indicated that the infections included a wide
range of subtypes consisting of three subtype families (Ia, Ib,
and Id) [3].
2.2. Cyclospora. Cyclospora cayetanensis is a sporulating
parasitic protozoan that infects the upper small intestinal
tract. It has been identiﬁed as both a food and waterborne
pathogen endemic in many developing countries. The dis-
ease ﬁrst came to medical attention in the 1970s [15]. It2 Interdisciplinary Perspectives on Infectious Diseases
is an important agent of Traveler’s Diarrhea in developed
countries and was responsible for numerous food borne
outbreaks in the United States and Canada in the late 1990s.
Approximately 1500 people during 1996 had Cyclospora
cayetanensis diarrhea from Guatemalan raspberries. This
epidemic recurred in 1997, emphasizing the risks of the
global economy and food supply [16]. The ribosomal DNA
of C. cayetanensis and three other species show a high degree
of homology within each other. The Cyclospora homology
and the lack of its sequence data from other species have
hindered identiﬁcation methods [17]. The incidence of
infection of Cyclospora is high in the warmer months.
Cyclosporiasis was found to be associated with ownership of
domestic animals, especially birds, guinea pigs, and rabbits
[18]. Many aspects of this disease and its transmission
remain still an enigma.
2.3. Entamoeba spp.
2.3.1. Entamoeba dispar. E. dispar exists in the colonic
lumen as a harmless saprophyte [19]. E. dispar and E.
histolyticaaremorphologicallyidenticalandphylogenetically
closely related (∼98% identity of rRNA sequences). Both
species have a similar host range but have vastly diﬀerent
properties with regard to pathogenicity in vivo [20]. Both
E. histolytica and E. dispar are able to colonize humans but
only E. histolytica is able to cause invasive disease (colitis
and extraintestinal manifestations). Tissue destruction is not
seen with E. dispar in vivo. Earlier a panel of researchers
concluded that colonization with E. dispar has never been
documented to cause invasive disease in humans therefore
the parasite does not necessitate treatment [21–23].
2.3.2. Entamoeba histolytica. The main purpose of detection
and diﬀerentiation of E. histolytica species in stool samples
is the detection of the causative agent of amoebic dysentery.
About 40–50 million people develop clinical amoebiasis each
year, resulting on up to 100000 deaths [24]. The causative
agent of amebic colitis and liver abscess is E. histolytica.T h e
non pathogenic parasites E. dispar and E. moshkovskii are
more common and identical in appearance to E. histolytica
[25, 26]. Invasive strains of E. histolytica may cause the
deaths; the value (above) for the prevalence of E. histolytica
is an overestimate since it dates from before the separation
of the pathogen E. histolytica from the nonpathogen E.
dispar [26]. Furthermore there are six additional species
of amebae (Entamoeba coli, Entamoeba hartmanni, Enta-
moeba polecki, Entamoeba chattoni, Iodamoeba butschlii and
Endolimax nana) that infect humans [27–37]. There are
otheramebaethatinfecthumans,thatis,Acanthamoebathat
cause intestinal infections in humans. E. nana and I. butschlii
colonize the human intestine and are nonpathogenic [38].
Infection due to E. dispar is 10 times more common than
E. histolyticain developed countries [39–43]. Similarly even
in a developing country E. histolytica and E. dispar can
be equally prevalent [35]. E. histolytica and E. dispar share
almost 90% genomic identity, and E. moshkovskii is also
closely genetically related [44].
2.3.3. Entamoeba moshkovskii. The free-living and parasitic
amoeba Entamoeba moshkovskii is indistinguishable in its
cyst and trophozoite forms from E. histolytica and E.
dispar. E. moshkovskii has recently been shown to be a
common infection of humans in the Indian subcontinent.
Early isolates of E. moshkovskii were from sewage [45]. E.
moshkovskii is osmotolerant and identiﬁed by growth at
room temperature and by riboprinting [45–48]. Human
isolates of E. moshkovskii have come from North America,
South Africa, Bangladesh, and Italy [49, 50]. The pathogenic
role of E. moshkovskii is yet to be deﬁned. To minimize the
confusion with E. histolytica/E. dispar a diagnostic tool is
needed. E. moshkovskii prevalence suggests that the infection
is common among children [50].
2.4. Giardia. Giardia is a binucleated ﬂagellated protozoan
and was discovered by Van Leeuwenhoek in 1681. Giar-
diasis is the most frequent cause of nonbacterial diarrhea
throughout the world [51]. Each year 500000 new cases are
reported and about 200 million people develop symptomatic
giardiasis [52]. These parasites can be found in mammals
and other animals, including reptiles and birds. Giardia
lamblia (syn. duodenalis or intestinalis) has two anterior
nuclei of equal size that contain complete copies of the
genome [53]. The parasite has a ventral adhesive disc
made of microtubules. There are four pairs of ﬂagella (one
anterior pair, two posterior pairs) and a caudal pair that
emerges from the disc. The complex working of the unique
Giardia cytoskeleton has been reviewed [54]. Giardia cysts
are resistant to chlorination and ozonolysis and can remain
viable for several weeks, especially in cold surface water.
The acquisition of Giardia occurs most commonly through
ingestionofthecystincontaminatedwaterorfood.Evenﬂies
can spread viable Giardia lamblia cysts on their exoskeleton,
which they have acquired naturally from unhygienic sources
[55]. There are two distinct genotypes of G. lamblia that
infect humans, commonly referred to as assemblages A
and B. Molecular analyses have shown the genetic variance
between the two assemblages to be greater than that used
to delineate other species of protozoa [56]. Furthermore,
it has been hypothesized that there may be phenotypic
diﬀerences between assemblages. One study showed an
association between intermittent diarrhoea and assemblage
A and between persistent diarrhoea and assemblage B [57].
Others studies showed that children with assemblage A were
more likely to be symptomatic [58]. A recent study showed
that the majority of G. lamblia infections in a northeastern
Brazilian community were assemblage B [59].
2.5. Isospora. Isosporiasis is a human intestinal disease
caused by the parasite Isospora belli. It is found worldwide,
especially in tropical and subtropical areas. It was ﬁrst
documented in 1915. Infection is seen most frequently in
immunocompromised individuals. I. belli is a coccidian
protozoa in phylum Apicomplexa that parasitizes epithelium
of upper small intestine of humans and causes diarrheal
disease. The entire life cycle of Isospora consists of asexual
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the same host. Transmission of I. belli oocysts seems to be
conﬁned to the anthroponotic cycle because humans are
the only known natural host [60]. The oocysts of I. belli
usually require less than one day to a few days to complete
sporogonic development and become infective [61, 62].
3.Methodological Approaches, with a Focus on
AmebiasisDiagnostics
3.1. Microscopic. For amebiasis, microscopy cannot dis-
tinguish E. histolytica from the more common parasites
E. dispar and E. moshkovskii. It is therefore an obsolete
approach to the diagnosis of amebiasis, but still conducted
in most parts of the world where modern diagnostic
approaches have failed to take hold. For microscopy each
stool sample should be divided into two portions. Direct
microscopy should be done by mixing a small amount
of the specimen in 0.9% sodium chloride solution (wet
mount) or Lugol’s iodine solution. This allows the detection
of motile trophozoites of Entamoeba histolytica/dispar and
can also provide information on the contents of the stool,
that is, the presence of leucocytes and red blood cells. The
second portion of the stool sample is then stained with
trichrome and/or iodine to identify trophozoites and cysts.
Three negative stool samples are required before it can be
accepted to report that there is no amoebic infection [63].
Trophozoites containing ingested RBCs are more common
with E. histolytica than E. dipar [64–66]. The sensitivity
of microscopy is as less as 60% and confounded with
misleading results due to misidentiﬁcation of macrophages
as trophozoites, (polymorphonuclear leukocytes) PMNs as
cysts (particularly when lobed nuclei of PMNs break apart),
and other “Entamoeba species” [64, 66–70].
3.2. Serology. The combination of serology and stool antigen
assays is more sensitive and speciﬁc than microscopy for the
diagnosis of Entamoeba histolytica infection [42]. The tests
of choice for serology are indirect ﬂuorescent antibody test
(IFAT), counter immunoelectrophoresis (CIEP), or enzyme
linked immunosorbent assay (ELISA). Serologic tests are
positive at the time of clinical presentation of amebiasis in
60–90% of cases, with positive serology seen in the overall
population of endemic areas of 5–10% (raising the issue of
both false positive and false negative results with serology).
3.2.1. Dipstick. Point of care tests to detect amebiasis would
be appropriate technology for the developing world. There
are at least two such tests that are in the early stages of
development [71, 72].
3.2.2. Rapid Antigen Detection. Stool oocyst and parasites
(O&Ps) exam cannot distinguish morphologically the three
closely related common amoebae: pathogenic E. histolytica
and commensal E. dispar and E. moshkovskii.D i ﬀerentiation
of E. histolytica from E. dispar most practically can be
accomplished by antigen detection. Currently there are
several antigen detection tests commercially available for in
vitro diagnostic use. The TechLab E. histolytica II test detects
exclusively E.histolytica[73,74].Commercialenzyme-linked
immunosorbent assays from Merlin and Alexon do not
diﬀerentiate between E. histolytica and E. dispar [75, 76].
Buss et al. concluded that the two ELISAs used in their
study were relatively quick and easy to perform but the
TechlabE.histolyticaIIELISAoutperformedtheR-Biopharm
Ridascreen Entamoeba test [77]. Sensitivity and speciﬁcity of
the TechLab kit have been studied from all over the world
viz. Bangladesh [73], Canada [42], the Netherlands [78], the
United Kingdom [79], and India [80].
E. histolytica infection can also be detected through
Gal/GalNAc lectin antigen in serum. The advantage is that
it is a more sensitive method than detection of antilectin
antibody for the early diagnosis of amebic liver abscess
(ALA). It is also more speciﬁc and uses a well-deﬁned
antigen, the Gal/GalNAc lectin. It can also, unlike antibody
detection tests, be used as a test of treatment [81]. A
disadvantage of this method is that the sensitivity of this
method is signiﬁcantly decreased in ALA patients after
initiation of antiamoebic therapy.
Salivary antigen has also been tested as a predictor for
invasive disease. In one of the studies it was found that the
presence of lectin in saliva had moderate sensitivity (65.8%)
and high speciﬁcity (97.4%) in early infections (<1w e e k
amebic colitis). Although the noninvasive sample collection
is an advantage, the sensitivity of this assay appears to be
lower than that of serum antigen detection [82].
3.3. PCR
3.3.1. Conventional PCR. Diagnosis of E. histolytica by PCR
testsstartedintheearly1990s.DiﬀerentiationofE.histolytica
from E. dispar by restriction fragment analysis of a single
gene ampliﬁed in vitro was ﬁrst reported in 1991 [83]. PCR-
based approaches have been endorsed by the WHO, and in
developed countries has found application in clinical and
epidemiological studies [84–87]. Identiﬁcation of E. histolyt-
ica can be done from various clinical specimens, such as
stool, tissues, and liver abscess aspirate [70]. Though PCR of
18S rDNA is expensive, it is as sensitive as ELISA techniques
[88–93]. PCR methods were found to be highly sensitive
and speciﬁc for detecting parasite DNA from microscopy-
positive samples using both manual and automated methods
[94–101]. PCR assays targeting 18S rDNA are widely used
for the detection and diﬀerentiation of Entamoeba species.
This can be easily detected from a DNA fragment of a single-
copy gene or from multicopy, extrachromosomal plasmids
in the amoebae [102]. Ampliﬁcation of E. histolytica and E.
dispar DNA fragments from human stool by conventional
PCR has been established to be a sensitive and speciﬁc
method for its detection [100]. Extraction of DNA was
performed directly from stool and ampliﬁed using primers
that amplify the extra chromosomal circular DNA [100, 101,
103]. Microscopically positive E. histolytica positive clinical
27/30 (90%) fecal specimens and 3/30 (10%) liver abscess
aspirates from Pharmongkutklao and Ramathibodi hospitals
in Bangkok, Thailand were evaluated by PCR. All specimens
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bymicroscopicexamination.Afterbeingtestedwithagenus-
speciﬁc PCR assay [35], 25/30 (83%) samples were positive
for Entamoeba spp. whereas 5/30 (16.6%) samples were
negative. By using the PCR assay developed successfully
identiﬁed 10/30 (33.3%) clinical samples tested: 4/10 (40%)
was positive for E. histolytica 6/10 (60%) for E. dispar. The
same results were obtained when previously described E.
histolytica-speciﬁc and E. dispar-speciﬁc primers were used
[104]. No ampliﬁcation of E. moshkovskii was observed with
any specimens [85].
For the simultaneous detection and diﬀerentiation of
E. histolytica and E. dispar from DNA extracted from
microscopy-positive fecal samples (fresh and formalin-ﬁxed)
multiplex PCR was developed with a reported sensitivity and
speciﬁcity of 94% and 100%, respectively [86, 105, 106].
Haque et al. identiﬁed E. moshkovskii in fecal specimens
using a riboprinting method [49]. A PCR test for the identi-
ﬁcation of E. moshkovskii in fecal samples was developed and
shown to have a high sensitivity and speciﬁcity using DNA
extracted directly from stool samples with the QIAGEN stool
extraction kit [106, 107]. A simpler PCR molecular detection
tool developed by Ali et al. for diagnosing E. moshkovskii
infections was used to detect the parasite directly in stool.
Out of 109 tested stool specimens from preschool children
in Bangladesh by PCR, E. histolytica was detected in 17/109
(15.6%), E. dispar in 39/109 (35.8%), E. moshkovskii in
23/109(21.1%),mixedinfectionofE.histolyticaandE.dispar
in 17 (73.9%), and E. dispar and E. moshkovskii coinfection
in 11/23 (48%) [50]. The high association of E. moshkovskii
with E. dispar may have obscured its identiﬁcation in
previous studies.
3.3.2. Real-Time PCR. The beauty of a newly developed real-
time PCR (qPCR) methodology for laboratory diagnosis of
infectious diseases is that it is more sensitive than conven-
tional PCR, is more rapid, leading to shorter turnaround
times, has a reduced risk of amplicon contamination from
laboratory environments, and has reduced reagent costs
[108]. Speciﬁc detection of the amplicon occurs, enabling
continuous monitoring of amplicon (PCR product) forma-
tion throughout the reaction. In comparison to conventional
PCR, real-time PCR is more sensitive and is also quan-
titative. Several qPCR methods have been designed [109–
111]. Clinical specimens may contain impurities that might
inhibit enzyme-based nucleic acid ampliﬁcation. Therefore,
the use of internal controls (ICs) for the routine diagnostic
PCR provides assurance that the clinical specimens are
successfully ampliﬁed and detected.
For single-plex real-time PCR detection of E. histolytica,
Qvarnstrom et al. used TaqMan probes targeting the 18S
rRNA gene, with the SYBR Green approach oﬀering a good
alternative (but not sequence-speciﬁc) to the TaqMan assay
[109].
Verweij et al. developed a multiplex qPCR assay for
detection of three diﬀerent intestinal parasites E. histolytica,
G. lamblia,a n dC. parvum. Their study showed 100%
(20/20) ampliﬁcation of E. histolytica and G. lamblia DNA
in microscopically positive isolates. Further, in 20 samples in
which modiﬁed acid-fast staining revealed Cryptosporidium
oocysts and in 4/7 (57%) samples from an immunocompro-
mised child with complaints of diarrhea, C. parvum DNA
was detected with the qPCR tested [111]. Verweij et al.
showed multiplex PCR 100% speciﬁcity and sensitivity for
E. histolytica and G. lamblia, and C. parvum [112].
Later Haque et al. produced a multiplex real-time PCR
assay for the detection of E. histolytica, G. lamblia,a n dC.
parvum. The detection limit for the multiplex real-time PCR
was 1 trophozoite of E. histolytica per extraction (100µL), 10
trophozoites of G. intestinalis per extraction, and 100 oocysts
of Cryptosporidium per extraction [21]. The multiplex qPCR
assaydemonstrated83/97(85%)agreementwithmicroscopy
for Giardia, with speciﬁcity for E. histolytica and G. lamblia,
and C. parvum of 98%, 97%, and 100%, respectively [21].
In another study qPCR for E. histolytica was positive in
20/23 (87%) liver abscess pus specimens, with the 3 negative
specimens from samples collected from patients who had
already received antiamebic therapy [108]. Results have been
highly speciﬁc and sensitive [40].
Stroup et al. developed a Cryptosporidium qPCR species-
speciﬁc probe assay that is sensitive and simple to perform.
The assay was done on 123 human stool specimens from
Bangladesh and Tanzania and exhibited a sensitivity and
speciﬁcity of >91% versus microscopy. Cryptosporidium
parvum-speciﬁc and Cryptosporidium meleagridis-speciﬁc
scorpion qPCR assays provided 100% accurate speciation
compared with Vspl RFLP analysis and sequencing [113].
An Isospora belli qPCR assay was performed with 21
positive and 120 negative stool samples and achieved 100%
speciﬁcity and sensitivity. PCR could supplement the clinical
laboratory diagnosis of isosporiasis, in particular in patients
with a history of diarrhea developing during or immediately
after travel to developing countries [114].
4. FutureApproaches
The burden of enteric protozoan infections is so great in
developed and developing countries that there is a need
for better diagnostic tests. The production of point-of-care
lateral ﬂow “dipstick” antigen detection tests and high-
throughput screening tests based on antigen detection or
PCR are clear priorities.
5. Conclusions
In the clinical laboratories the diagnosis of intestinal amebi-
asis should use a combination of detection of the parasite by
antigen detection or PCR (using E. histolytica speciﬁc tests)
and serological testing, and/or by colonoscopy and biopsy
of intestinal amebic lesions, and in the case of amebic liver
abscess by a combination of serology and drainage of the
liver abscess with testing of the ﬂuid for the parasite ideally
by PCR. The development of molecular tools, including
antigendetectionandPCRandqPCR,todetectE.histolytica,
E. dispar, E. moshkovskii, Giardia spp, and Cryptosporidium
spp. DNA in stool or liver abscess samples promises to
provide major advances. The amalgamation of many newInterdisciplinary Perspectives on Infectious Diseases 5
technologies into the diagnostic laboratory will represent a
challenge to all, but may lead to a better understanding of
the public health problems represented by these diseases.
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